The drug, rentosertib, was originally developed to treat idiopathic pulmonary fibrosis (IPF), a progressive scarring disease of the lungs, and was tested on 42 patients over 12 weeks in a Phase 2a trial.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.